Valuation : Bal Pharma Limited

Market Cap 957M 10.03M 8.61M 8.06M 7.38M 13.9M 13.94M 95.4M 37.29M 483M 37.64M 36.83M 1.6B P/E 2024
19.5x
P/E 2025 18.3x
Enterprise Value 2.38B 24.88M 21.36M 20M 18.31M 34.49M 34.59M 237M 92.56M 1.2B 93.42M 91.4M 3.96B EV / Sales 2024
0.78x
EV / Sales 2025 0.9x
Free-Float
34.72%
Yield 2024
1.32%
Yield 2025 1.44%
08-12 Bal Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
05-27 Bal Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
05-27 Bal Pharma Limited Recommends Dividend for the Financial Year 2025-26 CI
05-27 Bal Pharma Limited Appoints Shreepada Ml as Company Secretary and Compliance Officer, Effective May 27, 2026 CI
05-26 Bal Pharma Limited announced that it expects to receive INR 20.25 million in funding CI
05-12 Bal Pharma Limited Announces Resignation of Abdul Basith as Company Secretary & Compliance Officer, Effective May 11, 2026 CI
02-11 Bal Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
11-12 Bal Pharma Limited Appoints Bheekamchand Mukesh as Additional Director, Effective December 11, 2025 CI
11-12 Bal Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
25-09-30 Bal Pharma Limited Announces Cessation of H.S Venkatesh as Independent Director and Chairman/Member of the Audit Committee, Nomination and Remuneration Committee and Stake Holders Relationship Committee, with Effect from September 30, 2025 CI
25-08-11 Bal Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
25-05-29 Bal Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025 CI
25-05-29 Bal Pharma Limited Recommends Dividend for the Financial Year Ended March 31, 2025 CI
1 day-0.22%
1 week+0.01%
Current month-3.70%
1 month-4.29%
3 months-8.11%
6 months+11.31%
Current year+15.70%
1 week 84.01
Extreme 84.01
87.9
1 month 84.01
Extreme 84.01
93
Current year 60
Extreme 60
98.85
1 year 60
Extreme 60
98.85
3 years 60
Extreme 60
157.98
5 years 60
Extreme 60
157.98
10 years 23
Extreme 23
157.98
Manager TitleAgeSince
Chief Executive Officer 60 -
Director of Finance/CFO - 2023-06-01
Compliance Officer - 2026-06-22
Director TitleAgeSince
Director/Board Member 60 2011-06-29
Director/Board Member 65 2019-09-27
Director/Board Member - 2020-05-22
Change 5-day change 1-year change 3-year change Capi.($)
-0.22%+0.01% - - 14.08M
-1.12%-5.49%+60.19%+112.43% 1,048B
-1.57%-0.60%+50.33%+59.86% 640B
-1.81%-1.41%+24.07%+75.98% 456B
-1.17%-2.10%+38.61%+40.43% 362B
-2.00%-1.35%+22.22%+38.92% 295B
-0.98%+0.53%+2.04%+12.13% 255B
-0.76%+0.75%+51.75%+70.45% 236B
-3.18%-0.30%-17.23%-53.79% 204B
+0.52%+3.78%+30.67%+93.68% 185B
Average -1.23%-0.72%+29.18%+50.01% 409.07B
Weighted average by Cap. -1.36%-1.92%+38.50%+66.02%

Financials

2024 2025
Net sales 3.39B 35.52M 30.49M 28.54M 26.14M 49.24M 49.38M 338M 132M 1.71B 133M 130M 5.66B 3.03B 31.73M 27.24M 25.5M 23.35M 43.99M 44.12M 302M 118M 1.53B 119M 117M 5.06B
Net income 73.92M 774K 664K 622K 570K 1.07M 1.08M 7.37M 2.88M 37.26M 2.91M 2.84M 123M 72.15M 755K 648K 607K 556K 1.05M 1.05M 7.19M 2.81M 36.36M 2.84M 2.78M 120M
Net Debt 1.22B 12.81M 10.99M 10.29M 9.42M 17.75M 17.8M 122M 47.65M 616M 48.09M 47.05M 2.04B 1.42B 14.86M 12.75M 11.94M 10.93M 20.6M 20.65M 141M 55.27M 715M 55.78M 54.58M 2.37B
Logo Bal Pharma Limited
Bal Pharma Limited is a pharmaceutical company engaged in the manufacturing and selling of pharmaceutical products. The Company is engaged in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (API). It specializes in prescription drugs, generic & OTC products, intravenous infusion, and bulk actives. The Company offers a range of APIs including antihistamine, platelet inhibitor, anti-diabetic, anticonvulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, acne treatment, and others. It also offers a range of formulations covering dosage forms-tablets, capsules, syrups, suspensions, IV infusions, ophthalmics, creams and ointments to various semi-regulated markets. The API products are being exported to Japan, Australia, Spain, the United Kingdom, Canada, Nigeria, Iceland, Slovenia, Romania, Brazil, Pakistan, Germany, South Africa, Serbia, Taiwan, Malaysia, Thailand, among others.
Employees
986
Date Price Change Volume
26-08-28 84.83 -0.22% 1,886
26-08-27 ₹85.02 +1.74% 6,257
26-08-26 ₹83.57 -1.94% 10,024
26-08-25 ₹85.22 +0.04% 4,675
26-08-24 ₹85.19 -0.86% 8,338